37
Participants
Start Date
September 30, 2015
Primary Completion Date
December 7, 2016
Study Completion Date
July 17, 2017
DaxibotulinumtoxinA
Low, mid, and high dose sequential treatments of daxibotulinumtoxinA in dose-escalation safety and efficacy study
Wake forest Baptist Health, Winston-Salem
Coastal Neurology, Port Royal
Emory University, Atlanta
University of Florida Center for Movement Disorders & Neurorestoration, Gainesville
Precision Research Organization, Miami Lakes
University of South Florida, Tampa
Riverhills Healthcare, Inc., Cincinnati
Rush University Medical Center, Chicago
Kansas City Bone & Joint Clinic, Overland Park
The NeuroMedical Center Clinic, Baton Rouge
Parkinson's Disease Center and Movement Disorder Clinic, Houston
Colorado Springs Neurological Associates, Colorado Springs
The Parkinson's & Movement Disorder Institute, Fountain Valley
Revance Therapeutics, Inc.
INDUSTRY